His primary areas of study are Dementia, Alzheimer's disease, Internal medicine, Disease and Pathology. A large part of his Dementia studies is devoted to Cognitive decline. His Cognitive decline research is multidisciplinary, relying on both Intention-to-treat analysis, Cognition, Souvenaid, Severity of illness and Risk factor.
The various areas that Pieter Jelle Visser examines in his Alzheimer's disease study include Meta-analysis, Biomarker, Apolipoprotein E, Neuroscience and Atrophy. The Disease study combines topics in areas such as Clinical trial, Bioinformatics and Intensive care medicine. His work carried out in the field of Intensive care medicine brings together such families of science as Alzheimer's disease biomarkers, Florbetaben and Neuroimaging.
The scientist’s investigation covers issues in Dementia, Disease, Internal medicine, Alzheimer's disease and Pathology. His Dementia study integrates concerns from other disciplines, such as Psychiatry, Neurology, Cognition and Cohort. Pieter Jelle Visser combines subjects such as Hyperintensity and Audiology with his study of Cognition.
Pieter Jelle Visser has researched Disease in several fields, including Biomarker, Neuroimaging, Neuroscience and Intensive care medicine. His work deals with themes such as Endocrinology and Oncology, which intersect with Internal medicine. His Alzheimer's disease study combines topics from a wide range of disciplines, such as Gerontology and Atrophy.
Pieter Jelle Visser mostly deals with Disease, Internal medicine, Dementia, Cerebrospinal fluid and Amyloid. His Disease research is multidisciplinary, incorporating perspectives in Neuroimaging, Neuroscience, Proteomics and Bioinformatics. His Internal medicine research incorporates themes from Oldest old, Endocrinology, Cognition and Oncology.
The study incorporates disciplines such as Alzheimer's disease, Gerontology and Cohort in addition to Dementia. In his study, Csf biomarkers is strongly linked to Grey matter, which falls under the umbrella field of Alzheimer's disease. His Amyloid research incorporates elements of Positron emission tomography and Apolipoprotein E.
Pieter Jelle Visser focuses on Dementia, Internal medicine, Oncology, Disease and Cerebrospinal fluid. His research integrates issues of Alzheimer's disease, Clinical trial, Gerontology and Cohort in his study of Dementia. His Alzheimer's disease study combines topics from a wide range of disciplines, such as Executive functions, Neuropsychological assessment and Neuroimaging.
His Cohort research focuses on subjects like Cognitive decline, which are linked to Gait and Physical medicine and rehabilitation. The concepts of his Internal medicine study are interwoven with issues in Oldest old and Endocrinology. His Disease study incorporates themes from Cohort study, Bioinformatics, Proteomics, Biomarker and Positron emission tomography.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Bruno Dubois;Howard H. Feldman;Claudia Jacova;Steven T. DeKosky.
Lancet Neurology (2007)
Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment.
B. Winblad;K. Palmer;Miia Kivipelto;V. Jelic.
Journal of Internal Medicine (2004)
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Bruno Dubois;Bruno Dubois;Howard H Feldman;Claudia Jacova;Harald Hampel;Harald Hampel.
Lancet Neurology (2014)
Revising the definition of Alzheimer's disease: a new lexicon.
Bruno Dubois;Howard H. Feldman;Howard H. Feldman;Howard H. Feldman;Claudia Jacova;Jeffrey L. Cummings.
Lancet Neurology (2010)
A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease
Frank Jessen;Frank Jessen;Rebecca E. Amariglio;Martin van Boxtel;Monique Breteler.
Alzheimers & Dementia (2014)
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
Niklas Mattsson;Henrik Zetterberg;Oskar Hansson;Niels Andreasen.
Mild cognitive impairment
Pieter Jelle Visser.
Mild cognitive impairment (2006)
Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.
Willemijn J. Jansen;Rik Ossenkoppele;Dirk L. Knol;Betty M. Tijms.
Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study
Pieter Jelle Visser;Pieter Jelle Visser;Frans Verhey;Dirk L Knol;Philip Scheltens.
Lancet Neurology (2009)
Global and local gray matter loss in mild cognitive impairment and Alzheimer's disease.
G.B. Karas;P. Scheltens;S.A.R.B. Rombouts;P.J. Visser.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: